1097016-89-1

Basic information

• Product Name: 1-(2,5-diMethoxyphenyl)-2-(3-Methoxyphenyl)ethanone
• Synonyms: 1-(2,5-diMethoxyphenyl)-2-(3-Methoxyphenyl)ethanone
• CAS NO: 1097016-89-1
• Molecular Formula: C₁₇H₁₈O₄
• Molecular Weight: 286.32242
• Mol File: 1097016-89-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 430.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.128±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-(2,5-diMethoxyphenyl)-2-(3-Methoxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,5-diMethoxyphenyl)-2-(3-Methoxyphenyl)ethanone(1097016-89-1)
• EPA Substance Registry System: 1-(2,5-diMethoxyphenyl)-2-(3-Methoxyphenyl)ethanone(1097016-89-1)

Safety Data

• Hazardous Substances Data: 1097016-89-1(Hazardous Substances Data)

Usage

Description

1-(2,5-dimethoxyphenyl)-2-(3-methoxyphenyl)ethanone, also known as O-MeO-MMDA, is a synthetic chemical compound belonging to the phenethylamine family. It features two methoxy groups attached to a phenyl ring and an ethanone group, and is recognized for its psychedelic properties.

Uses

Used in Recreational Purposes:
1-(2,5-dimethoxyphenyl)-2-(3-methoxyphenyl)ethanone is used as a recreational drug for its hallucinogenic effects, which include altered perception and heightened sensory experiences. It acts on the serotonin receptors in the brain, leading to these psychoactive outcomes.
However, it is important to note that due to its psychoactive properties and associated health risks, 1-(2,5-dimethoxyphenyl)-2-(3-methoxyphenyl)ethanone is classified as a controlled substance in many countries. Its use can result in cognitive impairment, psychological dependence, and potential overdose, making it a substance that requires caution and regulation.

Upstream product

• 2785-98-0 2,5-dimethoxybenzoic acid 
• 1146443-78-8 N,2,5-trimethoxy-N-methylbenzamide 
• 824-98-6 m-methoxybenzyl chloride 
• 17918-14-8 2,5-dimethoxybenzoyl chloride 
• 150-78-7 1,4-dimethoxybezene 
• 6834-42-0 3-methoxyphenylacetic acid chloride 
• 1798-09-0 m-methoxyphenylacetic acid 

Downstream Products

• 1352306-12-7 1-(2,5-dihydroxyphenyl)-2-(3-hydroxyphenyl)ethanone 
• 1352306-11-6 1-(2-hydroxy-5-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)ethanone 
• 1352427-09-8 1-((2S)-1-(4-(4-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2H-chromen-2-yl)phenoxy)propan-2-yl)piperidine 
• 1352306-56-9 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-(piperidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol trifluoroacetate 
• 1352427-10-1 (3R)-3-methyl-1-((2S)-1-(4-(4-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2H-chromen-2-yl)phenoxy)propan-2-yl)pyrrolidine 
• 1352306-64-9 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol 
• 1352306-69-4 (R)-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol 
• 1352306-67-2 (S)-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol 
• 1352306-74-1 N-methyl-2-(4-(4-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2H-chromen-2-yl)phenoxy)ethanamine 
• 1352306-72-9 3-(3-hydroxyphenyl)-4-methyl-2-(4-(2-(methylamino)ethoxy)phenyl)-2H-chromen-6-ol trifluoroacetate 
• 1352306-14-9 2-(4-iodophenyl)-6-((tetrahydro-2H-pyran-2-yl)oxy)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)chroman-4-one 
• 1352307-51-7 2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-6-((tetrahydro-2H-pyran-2-yl)oxy)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)chroman-4-one 
• 1352307-50-6 3-(3-hydroxyphenyl)-4-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2H-chromen-6-ol trifluoroacetate 
• 1352306-15-0 3-(3-hydroxyphenyl)-2-(4-iodophenyl)-4-methyl-2H-chromen-6-ol 

Relevant articles and documents

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

The further optimization of ER-α degradation efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs). A fluoromethyl azetidine group was found to be preferred and resulted

HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

ESTROGEN RECEPTOR MODULATOR AND USES THEREOF

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in c